Multiple Sclerosis Features
Multiple sclerosis (MS) is the most common disabling neurological disease in young adults. It is characterised by demyelinating lesions disseminated in time and space.
✦ The Mnemonic
"DISSeminated in Time and Space — MISS: Motor, Internuclear, Sensory, Sphincter"
Motor · Internuclear ophthalmoplegia · Sensory · Sphincter/autonomic
Clinical Breakdown
McDonald criteria (2017): diagnosis requires dissemination in space (lesions in ≥2 CNS areas) and dissemination in time (lesions at different time points) — or CSF oligoclonal bands in place of DIT. MRI is central to diagnosis — periventricular, juxtacortical, infratentorial, and spinal cord lesions are the four characteristic locations.
Disease-modifying therapies (DMTs): interferon-beta and glatiramer acetate (injectable, low-moderate efficacy); natalizumab, fingolimod, dimethyl fumarate (high efficacy oral/IV); alemtuzumab, ocrelizumab, cladribine (very high efficacy, significant risk). Early aggressive therapy improves long-term outcomes.
Optic neuritis: unilateral painful vision loss over days, colour desaturation (red-green), relative afferent pupillary defect (RAPD — swinging light test). MRI of optic nerves shows enhancement. Most patients recover vision over weeks. 50% develop MS within 15 years if MRI brain is abnormal at presentation.
⭐ Clinical Pearl
Uhthoff's phenomenon: temporary worsening of neurological symptoms with heat (hot bath, exercise, fever). Caused by impaired conduction in demyelinated axons at elevated temperatures. This is NOT a relapse — symptoms resolve with cooling. Important to distinguish from true relapse when counselling patients.